Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Renee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer

29 May 2009 14:00

Elan Corporation, plc (NYSE: ELN) announced today that Renee P. Tannenbaum, Pharm.D., has joined the company as Executive Vice President and Chief Commercial Officer. Dr. Tannenbaum will be based at Elan's South San Francisco campus and report to Elan President Carlos Paya, MD, PhD.

Elan CEO Kelly Martin said that Dr. Tannenbaum was joining the company at a special time, as Elan establishes itself as one of only a few companies to successfully integrate a robust biotechnology pipeline and comprehensive commercial capabilities. "To be successful in the commercial arena," Mr. Martin said, "we need a leader with significant expertise in product launches, sales, marketing, managed markets, product development and commercialization, alliance management and leadership development. Of all the candidates we spoke with, Dr. Tannenbaum was unique in bringing demonstrated strengths in all these areas to the table."

Dr. Tannenbaum will be responsible for ensuring that Elan delivers on the revenue expectations for its marketed products, particularly Tysabri; preparing for the commercialization of the company's pipeline, including its Alzheimer's portfolio; and strengthening the company's overall commercial capabilities and commitment to strong performance. Elan's Commercial Operations, Strategic Brand Management and Commercial Strategy teams will report to Dr. Tannenbaum, and she will become a member of the BioPharma Leadership Team, headed by Dr. Paya.

Dr. Paya said that the company planned for the role of a Chief Commercial Officer to grow and lead Elan's commercial capabilities for some time. "Dr. Tannenbaum's experience, strategic perspective and specific commercial expertise-both in the U.S. and internationally-precisely meet Elan's needs today and moving forward," Dr. Paya said. "Her new role reflects an enhanced level of responsibility for ensuring our commercial opportunities are fully realized."

Dr. Tannenbaum joins Elan with more than 25 years of global pharmaceutical experience, most recently as Head of Global Commercial Operations for Novartis Pharma AG, a role she had held since joining the company three years ago.

Previously, Dr. Tannenbaum was with Bristol-Myers Squibb for nine years, in a range of executive commercial positions with increasing management and revenue-generation responsibility. These included: Vice President, Convatec, Americas; Vice President, Healthcare Channel Management, U.S. Pharmaceuticals; Regional Vice President of Sales, U.S. Primary Care; Vice President, Marketing, Avapro and Avalide; and Vice President, Marketing and Sales Force Effectiveness, Worldwide Medicines Group.

Earlier in her career, Dr. Tannenbaum was with Merck-Medco Managed Care for three years, preceded by 10 years at Merck & Co., with positions of increasing responsibility in marketing, market research, managed care, sales and clinical research. She is also Adjunct Clinical Assistant Professor at Philadelphia College of Pharmacy & Sciences, a division of University of the Sciences in Philadelphia (since 1981).

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com.

CONTACT: Elan Corporation, plc
Investors:
Chris Burns, 800-252-3526
David Marshall, 353-1-709-4403
or
Media:
Mary Stutts, 650-794-4403
Niamh Lyons, 353-1-553-3602

Copyright Business Wire 2009

Date   Source Headline
28th Jun 201610:25 amRNSResult of Annual General Meeting
3rd Jun 20163:25 pmRNSNotice of AGM
3rd Jun 201611:42 amRNSStatement re press speculation
31st May 20167:01 amRNSOlivier Serra joins as Chief Financial Officer
31st May 20167:00 amRNSFinal Audited Results
11th May 201610:48 amRNSHolding(s) in Company
10th May 201612:56 pmRNSHolding(s) in Company
10th May 201612:50 pmRNSHolding(s) in Company
29th Apr 20162:32 pmRNSResults of Placing
29th Apr 20167:00 amRNSPlacing to Raise $15m
28th Apr 20166:29 pmRNSPlacing to Raise $15m
27th Apr 20167:00 amRNSReserve and Corporate Update
25th Apr 201611:51 amRNSOpuama-3 Workover Update
20th Apr 20167:00 amRNSUbima Reserves & Resources Update
14th Apr 20167:00 amRNSOpuama-3 Workover Update
23rd Mar 20164:41 pmRNSSecond Price Monitoring Extn
23rd Mar 20164:35 pmRNSPrice Monitoring Extension
18th Mar 20164:26 pmRNSHolding(s) in Company
18th Mar 20164:26 pmRNSHolding(s) in Company
8th Mar 20164:40 pmRNSSecond Price Monitoring Extn
8th Mar 20164:35 pmRNSPrice Monitoring Extension
8th Mar 20161:46 pmRNSHolding(s) in Company
23rd Feb 20167:00 amRNSConversion of Shares
16th Feb 20167:00 amRNSOperational Update
5th Jan 201612:00 pmRNSIssue of Options
5th Jan 20167:00 amRNSBoard Changes
3rd Dec 201511:54 amRNSHolding(s) in Company
25th Nov 20154:43 pmRNSSecond Price Monitoring Extn
25th Nov 20154:37 pmRNSPrice Monitoring Extension
16th Nov 20157:00 amRNSOperational Update
5th Nov 20154:32 pmRNSHolding(s) in Company
13th Oct 20153:37 pmRNSTR-1: Notification of major interest in shares
9th Oct 201512:15 pmRNSTR-1: Notification of major interest in shares
30th Sep 20157:00 amRNSInterim results for the six months to 30 June 2015
28th Aug 20157:00 amRNSChange of Adviser
7th Aug 20157:00 amRNSOperations and Corporate Update
19th Jun 20152:14 pmRNSResult of AGM
28th May 20159:52 amRNSPosting of Financial Statements and Notice of AGM
27th May 20152:58 pmRNSHolding(s) in Company
26th May 20152:26 pmRNSNOTIFICATION OF MAJOR INTEREST IN SHARES
22nd May 20157:00 amRNSAudited Results for Year ended 31 December 2014
18th May 20152:02 pmRNSNOTIFICATION OF MAJOR INTEREST IN SHARES
14th May 20154:28 pmRNSHolding(s) in Company
11th May 20153:12 pmRNSHolding(s) in Company
11th May 20157:00 amRNSOML 40 Operatorship Update
23rd Apr 20158:08 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
21st Apr 20157:00 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th Apr 201510:47 amRNSHolding(s) in Company
11th Mar 20157:00 amRNSOperations and Corporate Update
8th Jan 20157:00 amRNS$75 million Reserves Based Lending Facility Agreed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.